#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Functional Connectivity When Detecting Rare Visual Targets in Schizophrenia Individuals with schizophrenia demonstrate difficulties in attending to important stimuli (e.g., targets) and ignoring distractors (e.g., non-targets).
1-1	0-10	Functional	_
1-2	11-23	Connectivity	_
1-3	24-28	When	_
1-4	29-38	Detecting	_
1-5	39-43	Rare	_
1-6	44-50	Visual	_
1-7	51-58	Targets	_
1-8	59-61	in	_
1-9	62-75	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-10	76-87	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-11	88-92	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	93-106	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	107-118	demonstrate	_
1-14	119-131	difficulties	_
1-15	132-134	in	_
1-16	135-144	attending	_
1-17	145-147	to	_
1-18	148-157	important	_
1-19	158-165	stimuli	_
1-20	166-167	(	_
1-21	168-172	e.g.	_
1-22	173-174	,	_
1-23	175-182	targets	_
1-24	183-184	)	_
1-25	185-188	and	_
1-26	189-197	ignoring	_
1-27	198-209	distractors	_
1-28	210-211	(	_
1-29	212-216	e.g.	_
1-30	217-218	,	_
1-31	219-230	non-targets	_
1-32	231-232	)	_
1-33	233-234	.	_

Text=We used a visual oddball task during fMRI to examine functional connectivity within and between the ventral and dorsal attention networks to determine the relative contribution of each network to detection of rare visual targets in schizophrenia.
2-1	235-237	We	_
2-2	238-242	used	_
2-3	243-244	a	_
2-4	245-251	visual	_
2-5	252-259	oddball	_
2-6	260-264	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
2-7	265-271	during	_
2-8	272-276	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-9	277-279	to	_
2-10	280-287	examine	_
2-11	288-298	functional	_
2-12	299-311	connectivity	_
2-13	312-318	within	_
2-14	319-322	and	_
2-15	323-330	between	_
2-16	331-334	the	_
2-17	335-342	ventral	_
2-18	343-346	and	_
2-19	347-353	dorsal	_
2-20	354-363	attention	_
2-21	364-372	networks	_
2-22	373-375	to	_
2-23	376-385	determine	_
2-24	386-389	the	_
2-25	390-398	relative	_
2-26	399-411	contribution	_
2-27	412-414	of	_
2-28	415-419	each	_
2-29	420-427	network	_
2-30	428-430	to	_
2-31	431-440	detection	_
2-32	441-443	of	_
2-33	444-448	rare	_
2-34	449-455	visual	_
2-35	456-463	targets	_
2-36	464-466	in	_
2-37	467-480	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-38	481-482	.	_

Text=The sample comprised 25 schizophrenia patients and 27 healthy controls.
3-1	483-486	The	_
3-2	487-493	sample	_
3-3	494-503	comprised	_
3-4	504-506	25	_
3-5	507-520	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-6	521-529	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-7	530-533	and	_
3-8	534-536	27	_
3-9	537-544	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-10	545-553	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-11	554-555	.	_

Text=Psychophysiological interaction analysis was used to examine whole-brain functional connectivity in response to targets.
4-1	556-575	Psychophysiological	_
4-2	576-587	interaction	_
4-3	588-596	analysis	_
4-4	597-600	was	_
4-5	601-605	used	_
4-6	606-608	to	_
4-7	609-616	examine	_
4-8	617-628	whole-brain	_
4-9	629-639	functional	_
4-10	640-652	connectivity	_
4-11	653-655	in	_
4-12	656-664	response	_
4-13	665-667	to	_
4-14	668-675	targets	_
4-15	676-677	.	_

Text=We used the right temporo parietal junction (TPJ) as the seed region for the ventral network and the right medial intraparietal sulcus (IPS) as the seed region for the dorsal network.
5-1	678-680	We	_
5-2	681-685	used	_
5-3	686-689	the	_
5-4	690-695	right	_
5-5	696-703	temporo	_
5-6	704-712	parietal	_
5-7	713-721	junction	_
5-8	722-723	(	_
5-9	724-727	TPJ	_
5-10	728-729	)	_
5-11	730-732	as	_
5-12	733-736	the	_
5-13	737-741	seed	_
5-14	742-748	region	_
5-15	749-752	for	_
5-16	753-756	the	_
5-17	757-764	ventral	_
5-18	765-772	network	_
5-19	773-776	and	_
5-20	777-780	the	_
5-21	781-786	right	_
5-22	787-793	medial	_
5-23	794-807	intraparietal	_
5-24	808-814	sulcus	_
5-25	815-816	(	_
5-26	817-820	IPS	_
5-27	821-822	)	_
5-28	823-825	as	_
5-29	826-829	the	_
5-30	830-834	seed	_
5-31	835-841	region	_
5-32	842-845	for	_
5-33	846-849	the	_
5-34	850-856	dorsal	_
5-35	857-864	network	_
5-36	865-866	.	_

Text=We found that connectivity between right IPS and right anterior insula (AI; a component of the ventral network) was significantly greater in controls than patients.
6-1	867-869	We	_
6-2	870-875	found	_
6-3	876-880	that	_
6-4	881-893	connectivity	_
6-5	894-901	between	_
6-6	902-907	right	_
6-7	908-911	IPS	_
6-8	912-915	and	_
6-9	916-921	right	_
6-10	922-930	anterior	_
6-11	931-937	insula	_
6-12	938-939	(	_
6-13	940-942	AI	_
6-14	943-944	;	_
6-15	945-946	a	_
6-16	947-956	component	_
6-17	957-959	of	_
6-18	960-963	the	_
6-19	964-971	ventral	_
6-20	972-979	network	_
6-21	980-981	)	_
6-22	982-985	was	_
6-23	986-999	significantly	_
6-24	1000-1007	greater	_
6-25	1008-1010	in	_
6-26	1011-1019	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-27	1020-1024	than	_
6-28	1025-1033	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-29	1034-1035	.	_

Text=Expected patterns of within- and between-network connectivity for right TPJ were observed in controls, and not significantly different in patients.
7-1	1036-1044	Expected	_
7-2	1045-1053	patterns	_
7-3	1054-1056	of	_
7-4	1057-1064	within-	_
7-5	1065-1068	and	_
7-6	1069-1084	between-network	_
7-7	1085-1097	connectivity	_
7-8	1098-1101	for	_
7-9	1102-1107	right	_
7-10	1108-1111	TPJ	_
7-11	1112-1116	were	_
7-12	1117-1125	observed	_
7-13	1126-1128	in	_
7-14	1129-1137	controls	_
7-15	1138-1139	,	_
7-16	1140-1143	and	_
7-17	1144-1147	not	_
7-18	1148-1161	significantly	_
7-19	1162-1171	different	_
7-20	1172-1174	in	_
7-21	1175-1183	patients	_
7-22	1184-1185	.	_

Text=These findings indicate functional connectivity deficits between the dorsal and ventral attention networks in schizophrenia that may create problems in processing relevant versus irrelevant stimuli.
8-1	1186-1191	These	_
8-2	1192-1200	findings	_
8-3	1201-1209	indicate	_
8-4	1210-1220	functional	_
8-5	1221-1233	connectivity	_
8-6	1234-1242	deficits	_
8-7	1243-1250	between	_
8-8	1251-1254	the	_
8-9	1255-1261	dorsal	_
8-10	1262-1265	and	_
8-11	1266-1273	ventral	_
8-12	1274-1283	attention	_
8-13	1284-1292	networks	_
8-14	1293-1295	in	_
8-15	1296-1309	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-16	1310-1314	that	_
8-17	1315-1318	may	_
8-18	1319-1325	create	_
8-19	1326-1334	problems	_
8-20	1335-1337	in	_
8-21	1338-1348	processing	_
8-22	1349-1357	relevant	_
8-23	1358-1364	versus	_
8-24	1365-1375	irrelevant	_
8-25	1376-1383	stimuli	_
8-26	1384-1385	.	_

Text=Understanding the nature of network disruptions underlying cognitive deficits of schizophrenia may help shed light on the pathophysiology of this disorder.
9-1	1386-1399	Understanding	_
9-2	1400-1403	the	_
9-3	1404-1410	nature	_
9-4	1411-1413	of	_
9-5	1414-1421	network	_
9-6	1422-1433	disruptions	_
9-7	1434-1444	underlying	_
9-8	1445-1454	cognitive	_
9-9	1455-1463	deficits	_
9-10	1464-1466	of	_
9-11	1467-1480	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-12	1481-1484	may	_
9-13	1485-1489	help	_
9-14	1490-1494	shed	_
9-15	1495-1500	light	_
9-16	1501-1503	on	_
9-17	1504-1507	the	_
9-18	1508-1523	pathophysiology	_
9-19	1524-1526	of	_
9-20	1527-1531	this	_
9-21	1532-1540	disorder	_
9-22	1541-1542	.	_

Text=2.
10-1	1543-1544	2	_
10-2	1545-1546	.	_

Text=Methods 2.1.
11-1	1547-1554	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-2	1555-1558	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-3	1559-1560	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

Text=Participants Twenty-five patients with schizophrenia (4 female) and 27 healthy controls (4 female) were recruited for the study.
12-1	1561-1573	Participants	_
12-2	1574-1585	Twenty-five	_
12-3	1586-1594	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-4	1595-1599	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-5	1600-1613	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-6	1614-1615	(	_
12-7	1616-1617	4	_
12-8	1618-1624	female	_
12-9	1625-1626	)	_
12-10	1627-1630	and	_
12-11	1631-1633	27	_
12-12	1634-1641	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-13	1642-1650	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-14	1651-1652	(	_
12-15	1653-1654	4	_
12-16	1655-1661	female	_
12-17	1662-1663	)	_
12-18	1664-1668	were	_
12-19	1669-1678	recruited	_
12-20	1679-1682	for	_
12-21	1683-1686	the	_
12-22	1687-1692	study	_
12-23	1693-1694	.	_

Text=The participants in this study were largely overlapping with those in Wynn et al.
13-1	1695-1698	The	_
13-2	1699-1711	participants	_
13-3	1712-1714	in	_
13-4	1715-1719	this	_
13-5	1720-1725	study	_
13-6	1726-1730	were	_
13-7	1731-1738	largely	_
13-8	1739-1750	overlapping	_
13-9	1751-1755	with	_
13-10	1756-1761	those	_
13-11	1762-1764	in	_
13-12	1765-1769	Wynn	_
13-13	1770-1772	et	_
13-14	1773-1775	al	_
13-15	1776-1777	.	_

Text=that examined regional activation and EEG, but did not consider connectivity.
14-1	1778-1782	that	_
14-2	1783-1791	examined	_
14-3	1792-1800	regional	_
14-4	1801-1811	activation	_
14-5	1812-1815	and	_
14-6	1816-1819	EEG	_
14-7	1820-1821	,	_
14-8	1822-1825	but	_
14-9	1826-1829	did	_
14-10	1830-1833	not	_
14-11	1834-1842	consider	_
14-12	1843-1855	connectivity	_
14-13	1856-1857	.	_

Text=Patients were recruited from outpatient treatment clinics at the Greater Los Angeles VA Medical Center (GLA) and the community.
15-1	1858-1866	Patients	_
15-2	1867-1871	were	_
15-3	1872-1881	recruited	_
15-4	1882-1886	from	_
15-5	1887-1897	outpatient	_
15-6	1898-1907	treatment	_
15-7	1908-1915	clinics	_
15-8	1916-1918	at	_
15-9	1919-1922	the	_
15-10	1923-1930	Greater	_
15-11	1931-1934	Los	_
15-12	1935-1942	Angeles	_
15-13	1943-1945	VA	_
15-14	1946-1953	Medical	_
15-15	1954-1960	Center	_
15-16	1961-1962	(	_
15-17	1963-1966	GLA	_
15-18	1967-1968	)	_
15-19	1969-1972	and	_
15-20	1973-1976	the	_
15-21	1977-1986	community	_
15-22	1987-1988	.	_

Text=Patients met diagnostic criteria for schizophrenia based on the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID).
16-1	1989-1997	Patients	_
16-2	1998-2001	met	_
16-3	2002-2012	diagnostic	_
16-4	2013-2021	criteria	_
16-5	2022-2025	for	_
16-6	2026-2039	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-7	2040-2045	based	_
16-8	2046-2048	on	_
16-9	2049-2052	the	_
16-10	2053-2063	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-11	2064-2072	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-12	2073-2082	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-13	2083-2086	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-14	2087-2093	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-15	2094-2098	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-16	2099-2100	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-17	2101-2110	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-18	2111-2112	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-19	2113-2117	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-20	2118-2119	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-21	2120-2121	.	_

Text=Selection criteria were the same as previous studies from this laboratory.
17-1	2122-2131	Selection	_
17-2	2132-2140	criteria	_
17-3	2141-2145	were	_
17-4	2146-2149	the	_
17-5	2150-2154	same	_
17-6	2155-2157	as	_
17-7	2158-2166	previous	_
17-8	2167-2174	studies	_
17-9	2175-2179	from	_
17-10	2180-2184	this	_
17-11	2185-2195	laboratory	_
17-12	2196-2197	.	_

Text=Patients were between 18 and 60 years of age, and were excluded from participation if they had: self-reported substance abuse in the past month or dependence in the last six months, IQ <70 based on examination of medical records, history of loss of consciousness for more than one hour, identifiable neurological disorders, or were not sufficiently fluent in English to consent and understand procedures.
18-1	2198-2206	Patients	_
18-2	2207-2211	were	_
18-3	2212-2219	between	_
18-4	2220-2222	18	_
18-5	2223-2226	and	_
18-6	2227-2229	60	_
18-7	2230-2235	years	_
18-8	2236-2238	of	_
18-9	2239-2242	age	_
18-10	2243-2244	,	_
18-11	2245-2248	and	_
18-12	2249-2253	were	_
18-13	2254-2262	excluded	_
18-14	2263-2267	from	_
18-15	2268-2281	participation	_
18-16	2282-2284	if	_
18-17	2285-2289	they	_
18-18	2290-2293	had	_
18-19	2294-2295	:	_
18-20	2296-2309	self-reported	_
18-21	2310-2319	substance	_
18-22	2320-2325	abuse	_
18-23	2326-2328	in	_
18-24	2329-2332	the	_
18-25	2333-2337	past	_
18-26	2338-2343	month	_
18-27	2344-2346	or	_
18-28	2347-2357	dependence	_
18-29	2358-2360	in	_
18-30	2361-2364	the	_
18-31	2365-2369	last	_
18-32	2370-2373	six	_
18-33	2374-2380	months	_
18-34	2381-2382	,	_
18-35	2383-2385	IQ	_
18-36	2386-2387	<	_
18-37	2388-2390	70	_
18-38	2391-2396	based	_
18-39	2397-2399	on	_
18-40	2400-2411	examination	_
18-41	2412-2414	of	_
18-42	2415-2422	medical	_
18-43	2423-2430	records	_
18-44	2431-2432	,	_
18-45	2433-2440	history	_
18-46	2441-2443	of	_
18-47	2444-2448	loss	_
18-48	2449-2451	of	_
18-49	2452-2465	consciousness	_
18-50	2466-2469	for	_
18-51	2470-2474	more	_
18-52	2475-2479	than	_
18-53	2480-2483	one	_
18-54	2484-2488	hour	_
18-55	2489-2490	,	_
18-56	2491-2503	identifiable	_
18-57	2504-2516	neurological	_
18-58	2517-2526	disorders	_
18-59	2527-2528	,	_
18-60	2529-2531	or	_
18-61	2532-2536	were	_
18-62	2537-2540	not	_
18-63	2541-2553	sufficiently	_
18-64	2554-2560	fluent	_
18-65	2561-2563	in	_
18-66	2564-2571	English	_
18-67	2572-2574	to	_
18-68	2575-2582	consent	_
18-69	2583-2586	and	_
18-70	2587-2597	understand	_
18-71	2598-2608	procedures	_
18-72	2609-2610	.	_

Text=Psychiatric symptoms were evaluated using the 24-item University of California, Los Angeles (UCLA) version of the Brief Psychiatric Rating Scale (BPRS) and Scale for the Assessment of Negative Symptoms (SANS).
19-1	2611-2622	Psychiatric	_
19-2	2623-2631	symptoms	_
19-3	2632-2636	were	_
19-4	2637-2646	evaluated	_
19-5	2647-2652	using	_
19-6	2653-2656	the	_
19-7	2657-2664	24-item	_
19-8	2665-2675	University	_
19-9	2676-2678	of	_
19-10	2679-2689	California	_
19-11	2690-2691	,	_
19-12	2692-2695	Los	_
19-13	2696-2703	Angeles	_
19-14	2704-2705	(	_
19-15	2706-2710	UCLA	_
19-16	2711-2712	)	_
19-17	2713-2720	version	_
19-18	2721-2723	of	_
19-19	2724-2727	the	_
19-20	2728-2733	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-21	2734-2745	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-22	2746-2752	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-23	2753-2758	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-24	2759-2760	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-25	2761-2765	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-26	2766-2767	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-27	2768-2771	and	_
19-28	2772-2777	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-29	2778-2781	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-30	2782-2785	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-31	2786-2796	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-32	2797-2799	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-33	2800-2808	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-34	2809-2817	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-35	2818-2819	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-36	2820-2824	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-37	2825-2826	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-38	2827-2828	.	_

Text=For the BPRS we report means for the “ positive symptom, ” “ negative symptom, ” “ agitation/mania, ” and “ depression/anxiety ” factors.
20-1	2829-2832	For	_
20-2	2833-2836	the	_
20-3	2837-2841	BPRS	_
20-4	2842-2844	we	_
20-5	2845-2851	report	_
20-6	2852-2857	means	_
20-7	2858-2861	for	_
20-8	2862-2865	the	_
20-9	2866-2867	“	_
20-10	2868-2876	positive	_
20-11	2877-2884	symptom	_
20-12	2885-2886	,	_
20-13	2887-2888	”	_
20-14	2889-2890	“	_
20-15	2891-2899	negative	_
20-16	2900-2907	symptom	_
20-17	2908-2909	,	_
20-18	2910-2911	”	_
20-19	2912-2913	“	_
20-20	2914-2929	agitation/mania	_
20-21	2930-2931	,	_
20-22	2932-2933	”	_
20-23	2934-2937	and	_
20-24	2938-2939	“	_
20-25	2940-2958	depression/anxiety	_
20-26	2959-2960	”	_
20-27	2961-2968	factors	_
20-28	2969-2970	.	_

Text=For the SANS we report four global scales: Affective Flattening, Alogia, Avolition-Apathy, and Anhedonia-Asociality.
21-1	2971-2974	For	_
21-2	2975-2978	the	_
21-3	2979-2983	SANS	_
21-4	2984-2986	we	_
21-5	2987-2993	report	_
21-6	2994-2998	four	_
21-7	2999-3005	global	_
21-8	3006-3012	scales	_
21-9	3013-3014	:	_
21-10	3015-3024	Affective	_
21-11	3025-3035	Flattening	_
21-12	3036-3037	,	_
21-13	3038-3044	Alogia	_
21-14	3045-3046	,	_
21-15	3047-3063	Avolition-Apathy	_
21-16	3064-3065	,	_
21-17	3066-3069	and	_
21-18	3070-3090	Anhedonia-Asociality	_
21-19	3091-3092	.	_

Text=Healthy controls between 18 and 60 years of age were recruited through internet postings and interviewed with the SCID-I and portions of the Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II).
22-1	3093-3100	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
22-2	3101-3109	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
22-3	3110-3117	between	_
22-4	3118-3120	18	_
22-5	3121-3124	and	_
22-6	3125-3127	60	_
22-7	3128-3133	years	_
22-8	3134-3136	of	_
22-9	3137-3140	age	_
22-10	3141-3145	were	_
22-11	3146-3155	recruited	_
22-12	3156-3163	through	_
22-13	3164-3172	internet	_
22-14	3173-3181	postings	_
22-15	3182-3185	and	_
22-16	3186-3197	interviewed	_
22-17	3198-3202	with	_
22-18	3203-3206	the	_
22-19	3207-3213	SCID-I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-20	3214-3217	and	_
22-21	3218-3226	portions	_
22-22	3227-3229	of	_
22-23	3230-3233	the	_
22-24	3234-3244	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-25	3245-3253	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-26	3254-3263	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-27	3264-3267	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-28	3268-3274	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-29	3275-3279	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-30	3280-3282	II	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-31	3283-3292	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-32	3293-3294	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-33	3295-3302	SCID-II	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-34	3303-3304	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-35	3305-3306	.	_

Text=Exclusion criteria for potential controls included: an identifiable neurological disorder or head injury, a first-degree relative with schizophrenia or another psychotic disorder, insufficient fluency in English, a personal history of schizophrenia or other psychotic disorder, bipolar disorder, recurrent depression, a lifetime history of substance dependence, or any substance abuse in the last 6 months, and any of the following Axis II disorders: avoidant, paranoid, schizoid, or schizotypal.
23-1	3307-3316	Exclusion	_
23-2	3317-3325	criteria	_
23-3	3326-3329	for	_
23-4	3330-3339	potential	_
23-5	3340-3348	controls	_
23-6	3349-3357	included	_
23-7	3358-3359	:	_
23-8	3360-3362	an	_
23-9	3363-3375	identifiable	_
23-10	3376-3388	neurological	_
23-11	3389-3397	disorder	_
23-12	3398-3400	or	_
23-13	3401-3405	head	_
23-14	3406-3412	injury	_
23-15	3413-3414	,	_
23-16	3415-3416	a	_
23-17	3417-3429	first-degree	_
23-18	3430-3438	relative	_
23-19	3439-3443	with	_
23-20	3444-3457	schizophrenia	_
23-21	3458-3460	or	_
23-22	3461-3468	another	_
23-23	3469-3478	psychotic	_
23-24	3479-3487	disorder	_
23-25	3488-3489	,	_
23-26	3490-3502	insufficient	_
23-27	3503-3510	fluency	_
23-28	3511-3513	in	_
23-29	3514-3521	English	_
23-30	3522-3523	,	_
23-31	3524-3525	a	_
23-32	3526-3534	personal	_
23-33	3535-3542	history	_
23-34	3543-3545	of	_
23-35	3546-3559	schizophrenia	_
23-36	3560-3562	or	_
23-37	3563-3568	other	_
23-38	3569-3578	psychotic	_
23-39	3579-3587	disorder	_
23-40	3588-3589	,	_
23-41	3590-3597	bipolar	_
23-42	3598-3606	disorder	_
23-43	3607-3608	,	_
23-44	3609-3618	recurrent	_
23-45	3619-3629	depression	_
23-46	3630-3631	,	_
23-47	3632-3633	a	_
23-48	3634-3642	lifetime	_
23-49	3643-3650	history	_
23-50	3651-3653	of	_
23-51	3654-3663	substance	_
23-52	3664-3674	dependence	_
23-53	3675-3676	,	_
23-54	3677-3679	or	_
23-55	3680-3683	any	_
23-56	3684-3693	substance	_
23-57	3694-3699	abuse	_
23-58	3700-3702	in	_
23-59	3703-3706	the	_
23-60	3707-3711	last	_
23-61	3712-3713	6	_
23-62	3714-3720	months	_
23-63	3721-3722	,	_
23-64	3723-3726	and	_
23-65	3727-3730	any	_
23-66	3731-3733	of	_
23-67	3734-3737	the	_
23-68	3738-3747	following	_
23-69	3748-3752	Axis	_
23-70	3753-3755	II	_
23-71	3756-3765	disorders	_
23-72	3766-3767	:	_
23-73	3768-3776	avoidant	_
23-74	3777-3778	,	_
23-75	3779-3787	paranoid	_
23-76	3788-3789	,	_
23-77	3790-3798	schizoid	_
23-78	3799-3800	,	_
23-79	3801-3803	or	_
23-80	3804-3815	schizotypal	_
23-81	3816-3817	.	_

Text=All interviewers were trained through the Treatment Unit of the Department of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center (MIRECC) to a minimum kappa of 0.75 for key psychotic and mood items.
24-1	3818-3821	All	_
24-2	3822-3834	interviewers	_
24-3	3835-3839	were	_
24-4	3840-3847	trained	_
24-5	3848-3855	through	_
24-6	3856-3859	the	_
24-7	3860-3869	Treatment	_
24-8	3870-3874	Unit	_
24-9	3875-3877	of	_
24-10	3878-3881	the	_
24-11	3882-3892	Department	_
24-12	3893-3895	of	_
24-13	3896-3904	Veterans	_
24-14	3905-3912	Affairs	_
24-15	3913-3917	VISN	_
24-16	3918-3920	22	_
24-17	3921-3927	Mental	_
24-18	3928-3935	Illness	_
24-19	3936-3944	Research	_
24-20	3945-3946	,	_
24-21	3947-3956	Education	_
24-22	3957-3958	,	_
24-23	3959-3962	and	_
24-24	3963-3971	Clinical	_
24-25	3972-3978	Center	_
24-26	3979-3980	(	_
24-27	3981-3987	MIRECC	_
24-28	3988-3989	)	_
24-29	3990-3992	to	_
24-30	3993-3994	a	_
24-31	3995-4002	minimum	_
24-32	4003-4008	kappa	_
24-33	4009-4011	of	_
24-34	4012-4016	0.75	_
24-35	4017-4020	for	_
24-36	4021-4024	key	_
24-37	4025-4034	psychotic	_
24-38	4035-4038	and	_
24-39	4039-4043	mood	_
24-40	4044-4049	items	_
24-41	4050-4051	.	_

Text=The study protocol was reviewed and approved by the Institutional Review Boards of the University of California, Los Angeles and Greater Los Angeles VA Medical Center.
25-1	4052-4055	The	_
25-2	4056-4061	study	_
25-3	4062-4070	protocol	_
25-4	4071-4074	was	_
25-5	4075-4083	reviewed	_
25-6	4084-4087	and	_
25-7	4088-4096	approved	_
25-8	4097-4099	by	_
25-9	4100-4103	the	_
25-10	4104-4117	Institutional	_
25-11	4118-4124	Review	_
25-12	4125-4131	Boards	_
25-13	4132-4134	of	_
25-14	4135-4138	the	_
25-15	4139-4149	University	_
25-16	4150-4152	of	_
25-17	4153-4163	California	_
25-18	4164-4165	,	_
25-19	4166-4169	Los	_
25-20	4170-4177	Angeles	_
25-21	4178-4181	and	_
25-22	4182-4189	Greater	_
25-23	4190-4193	Los	_
25-24	4194-4201	Angeles	_
25-25	4202-4204	VA	_
25-26	4205-4212	Medical	_
25-27	4213-4219	Center	_
25-28	4220-4221	.	_

Text=All participants had the capacity to give informed consent and provided written informed consent after all procedures were fully explained.
26-1	4222-4225	All	_
26-2	4226-4238	participants	_
26-3	4239-4242	had	_
26-4	4243-4246	the	_
26-5	4247-4255	capacity	_
26-6	4256-4258	to	_
26-7	4259-4263	give	_
26-8	4264-4272	informed	_
26-9	4273-4280	consent	_
26-10	4281-4284	and	_
26-11	4285-4293	provided	_
26-12	4294-4301	written	_
26-13	4302-4310	informed	_
26-14	4311-4318	consent	_
26-15	4319-4324	after	_
26-16	4325-4328	all	_
26-17	4329-4339	procedures	_
26-18	4340-4344	were	_
26-19	4345-4350	fully	_
26-20	4351-4360	explained	_
26-21	4361-4362	.	_

Text=2.2.
27-1	4363-4366	2.2	_
27-2	4367-4368	.	_

Text=Procedures 2.2.1.
28-1	4369-4379	Procedures	_
28-2	4380-4385	2.2.1	_
28-3	4386-4387	.	_

Text=Task design Participants completed a visual oddball task, modeled after prior studies, in which they viewed images of two letters, X and K; one letter served as a target and the other as a nontarget in a counterbalanced fashion.
29-1	4388-4392	Task	_
29-2	4393-4399	design	_
29-3	4400-4412	Participants	_
29-4	4413-4422	completed	_
29-5	4423-4424	a	_
29-6	4425-4431	visual	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-7	4432-4439	oddball	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-8	4440-4444	task	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-9	4445-4446	,	_
29-10	4447-4454	modeled	_
29-11	4455-4460	after	_
29-12	4461-4466	prior	_
29-13	4467-4474	studies	_
29-14	4475-4476	,	_
29-15	4477-4479	in	_
29-16	4480-4485	which	_
29-17	4486-4490	they	_
29-18	4491-4497	viewed	_
29-19	4498-4504	images	_
29-20	4505-4507	of	_
29-21	4508-4511	two	_
29-22	4512-4519	letters	_
29-23	4520-4521	,	_
29-24	4522-4523	X	_
29-25	4524-4527	and	_
29-26	4528-4529	K	_
29-27	4530-4531	;	_
29-28	4532-4535	one	_
29-29	4536-4542	letter	_
29-30	4543-4549	served	_
29-31	4550-4552	as	_
29-32	4553-4554	a	_
29-33	4555-4561	target	_
29-34	4562-4565	and	_
29-35	4566-4569	the	_
29-36	4570-4575	other	_
29-37	4576-4578	as	_
29-38	4579-4580	a	_
29-39	4581-4590	nontarget	_
29-40	4591-4593	in	_
29-41	4594-4595	a	_
29-42	4596-4611	counterbalanced	_
29-43	4612-4619	fashion	_
29-44	4620-4621	.	_

Text=We used an event-related design and presented the stimuli in three separate blocks using magnet-compatible goggles (Resonance Technology, Northridge, CA).
30-1	4622-4624	We	_
30-2	4625-4629	used	_
30-3	4630-4632	an	_
30-4	4633-4646	event-related	_
30-5	4647-4653	design	_
30-6	4654-4657	and	_
30-7	4658-4667	presented	_
30-8	4668-4671	the	_
30-9	4672-4679	stimuli	_
30-10	4680-4682	in	_
30-11	4683-4688	three	_
30-12	4689-4697	separate	_
30-13	4698-4704	blocks	_
30-14	4705-4710	using	_
30-15	4711-4728	magnet-compatible	_
30-16	4729-4736	goggles	_
30-17	4737-4738	(	_
30-18	4739-4748	Resonance	_
30-19	4749-4759	Technology	_
30-20	4760-4761	,	_
30-21	4762-4772	Northridge	_
30-22	4773-4774	,	_
30-23	4775-4777	CA	_
30-24	4778-4779	)	_
30-25	4780-4781	.	_

Text=Each stimulus was displayed for 100 ms followed by an interstimulus interval (ISI) that was either 900, 1900, or 2900 ms (mean ISI = 1900 ms).
31-1	4782-4786	Each	_
31-2	4787-4795	stimulus	_
31-3	4796-4799	was	_
31-4	4800-4809	displayed	_
31-5	4810-4813	for	_
31-6	4814-4817	100	_
31-7	4818-4820	ms	_
31-8	4821-4829	followed	_
31-9	4830-4832	by	_
31-10	4833-4835	an	_
31-11	4836-4849	interstimulus	_
31-12	4850-4858	interval	_
31-13	4859-4860	(	_
31-14	4861-4864	ISI	_
31-15	4865-4866	)	_
31-16	4867-4871	that	_
31-17	4872-4875	was	_
31-18	4876-4882	either	_
31-19	4883-4886	900	_
31-20	4887-4888	,	_
31-21	4889-4893	1900	_
31-22	4894-4895	,	_
31-23	4896-4898	or	_
31-24	4899-4903	2900	_
31-25	4904-4906	ms	_
31-26	4907-4908	(	_
31-27	4909-4913	mean	_
31-28	4914-4917	ISI	_
31-29	4918-4919	=	_
31-30	4920-4924	1900	_
31-31	4925-4927	ms	_
31-32	4928-4929	)	_
31-33	4930-4931	.	_

Text=The ISIs were equiprobable and randomly distributed.
32-1	4932-4935	The	_
32-2	4936-4940	ISIs	_
32-3	4941-4945	were	_
32-4	4946-4958	equiprobable	_
32-5	4959-4962	and	_
32-6	4963-4971	randomly	_
32-7	4972-4983	distributed	_
32-8	4984-4985	.	_

Text=Participants were instructed to push a button on a MRI-compatible button box whenever they detected the target and had 3000 ms to make a response1.
33-1	4986-4998	Participants	_
33-2	4999-5003	were	_
33-3	5004-5014	instructed	_
33-4	5015-5017	to	_
33-5	5018-5022	push	_
33-6	5023-5024	a	_
33-7	5025-5031	button	_
33-8	5032-5034	on	_
33-9	5035-5036	a	_
33-10	5037-5051	MRI-compatible	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-11	5052-5058	button	_
33-12	5059-5062	box	_
33-13	5063-5071	whenever	_
33-14	5072-5076	they	_
33-15	5077-5085	detected	_
33-16	5086-5089	the	_
33-17	5090-5096	target	_
33-18	5097-5100	and	_
33-19	5101-5104	had	_
33-20	5105-5109	3000	_
33-21	5110-5112	ms	_
33-22	5113-5115	to	_
33-23	5116-5120	make	_
33-24	5121-5122	a	_
33-25	5123-5132	response1	_
33-26	5133-5134	.	_

Text=Within each block a total of 150 stimuli were presented: 12% were targets (n = 18) and 88% were non-targets (n = 132).
34-1	5135-5141	Within	_
34-2	5142-5146	each	_
34-3	5147-5152	block	_
34-4	5153-5154	a	_
34-5	5155-5160	total	_
34-6	5161-5163	of	_
34-7	5164-5167	150	_
34-8	5168-5175	stimuli	_
34-9	5176-5180	were	_
34-10	5181-5190	presented	_
34-11	5191-5192	:	_
34-12	5193-5195	12	_
34-13	5196-5197	%	_
34-14	5198-5202	were	_
34-15	5203-5210	targets	_
34-16	5211-5212	(	_
34-17	5213-5214	n	_
34-18	5215-5216	=	_
34-19	5217-5219	18	_
34-20	5220-5221	)	_
34-21	5222-5225	and	_
34-22	5226-5228	88	_
34-23	5229-5230	%	_
34-24	5231-5235	were	_
34-25	5236-5247	non-targets	_
34-26	5248-5249	(	_
34-27	5250-5251	n	_
34-28	5252-5253	=	_
34-29	5254-5257	132	_
34-30	5258-5259	)	_
34-31	5260-5261	.	_

Text=Additionally, null trials were interspersed throughout each block and consisted solely of a fixation point.
35-1	5262-5274	Additionally	_
35-2	5275-5276	,	_
35-3	5277-5281	null	_
35-4	5282-5288	trials	_
35-5	5289-5293	were	_
35-6	5294-5306	interspersed	_
35-7	5307-5317	throughout	_
35-8	5318-5322	each	_
35-9	5323-5328	block	_
35-10	5329-5332	and	_
35-11	5333-5342	consisted	_
35-12	5343-5349	solely	_
35-13	5350-5352	of	_
35-14	5353-5354	a	_
35-15	5355-5363	fixation	_
35-16	5364-5369	point	_
35-17	5370-5371	.	_

Text=Duration of each block was 5 minutes.
36-1	5372-5380	Duration	_
36-2	5381-5383	of	_
36-3	5384-5388	each	_
36-4	5389-5394	block	_
36-5	5395-5398	was	_
36-6	5399-5400	5	_
36-7	5401-5408	minutes	_
36-8	5409-5410	.	_

Text=The task took approximately 20 minutes to complete.
37-1	5411-5414	The	_
37-2	5415-5419	task	_
37-3	5420-5424	took	_
37-4	5425-5438	approximately	_
37-5	5439-5441	20	_
37-6	5442-5449	minutes	_
37-7	5450-5452	to	_
37-8	5453-5461	complete	_
37-9	5462-5463	.	_

Text=2.2.2. fMRI data acquisition and preprocessing Scanning was performed on a Siemens 3T (Erlangen, Germany) Trio MRI scanner.
38-1	5464-5470	2.2.2.	_
38-2	5471-5475	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
38-3	5476-5480	data	_
38-4	5481-5492	acquisition	_
38-5	5493-5496	and	_
38-6	5497-5510	preprocessing	_
38-7	5511-5519	Scanning	_
38-8	5520-5523	was	_
38-9	5524-5533	performed	_
38-10	5534-5536	on	_
38-11	5537-5538	a	_
38-12	5539-5546	Siemens	_
38-13	5547-5549	3T	http://maven.renci.org/NeuroBridge/neurobridge#Thing
38-14	5550-5551	(	_
38-15	5552-5560	Erlangen	_
38-16	5561-5562	,	_
38-17	5563-5570	Germany	_
38-18	5571-5572	)	_
38-19	5573-5577	Trio	_
38-20	5578-5581	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-21	5582-5589	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-22	5590-5591	.	_

Text=Functional runs (blocks) were acquired with 150 T2 * -weighted echoplanar images (EPIs) [repetition time (TR) 2000 ms; echo time (TE) 30 ms; flip angle = 75°; 33 slices; slice thickness 4mm; matrix 64 × 64; FOV 220 mm].
39-1	5592-5602	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-2	5603-5607	runs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-3	5608-5609	(	_
39-4	5610-5616	blocks	_
39-5	5617-5618	)	_
39-6	5619-5623	were	_
39-7	5624-5632	acquired	_
39-8	5633-5637	with	_
39-9	5638-5641	150	_
39-10	5642-5644	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-11	5645-5646	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-12	5647-5656	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-13	5657-5667	echoplanar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-14	5668-5674	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-15	5675-5676	(	_
39-16	5677-5681	EPIs	_
39-17	5682-5683	)	_
39-18	5684-5685	[	_
39-19	5686-5696	repetition	_
39-20	5697-5701	time	_
39-21	5702-5703	(	_
39-22	5704-5706	TR	_
39-23	5707-5708	)	_
39-24	5709-5713	2000	_
39-25	5714-5716	ms	_
39-26	5717-5718	;	_
39-27	5719-5723	echo	_
39-28	5724-5728	time	_
39-29	5729-5730	(	_
39-30	5731-5733	TE	_
39-31	5734-5735	)	_
39-32	5736-5738	30	_
39-33	5739-5741	ms	_
39-34	5742-5743	;	_
39-35	5744-5748	flip	_
39-36	5749-5754	angle	_
39-37	5755-5756	=	_
39-38	5757-5760	75°	_
39-39	5761-5762	;	_
39-40	5763-5765	33	_
39-41	5766-5772	slices	_
39-42	5773-5774	;	_
39-43	5775-5780	slice	_
39-44	5781-5790	thickness	_
39-45	5791-5794	4mm	_
39-46	5795-5796	;	_
39-47	5797-5803	matrix	_
39-48	5804-5806	64	_
39-49	5807-5808	×	_
39-50	5809-5811	64	_
39-51	5812-5813	;	_
39-52	5814-5817	FOV	_
39-53	5818-5821	220	_
39-54	5822-5824	mm	_
39-55	5825-5826	]	_
39-56	5827-5828	.	_

Text=The first two volumes of each functional scan are automatically discarded before data collection begins to allow for T1 equilibrium.
40-1	5829-5832	The	_
40-2	5833-5838	first	_
40-3	5839-5842	two	_
40-4	5843-5850	volumes	_
40-5	5851-5853	of	_
40-6	5854-5858	each	_
40-7	5859-5869	functional	_
40-8	5870-5874	scan	_
40-9	5875-5878	are	_
40-10	5879-5892	automatically	_
40-11	5893-5902	discarded	_
40-12	5903-5909	before	_
40-13	5910-5914	data	_
40-14	5915-5925	collection	_
40-15	5926-5932	begins	_
40-16	5933-5935	to	_
40-17	5936-5941	allow	_
40-18	5942-5945	for	_
40-19	5946-5948	T1	_
40-20	5949-5960	equilibrium	_
40-21	5961-5962	.	_

Text=Two sets of structural images were acquired for registration of functional data: a T1 weighted magnetization prepared rapid-acquisition gradient echo image (MPRAGE) [TR, 1900 ms; TE 3.43 ms; flip angle = 9°; 160 sagittal slices; slice thickness 1 mm; matrix 256 × 256; FOV 256 mm]; and a T2-weighted matched-bandwidth high-resolution scan with the same slice prescription as the EPI [TR, 6540 ms; TE, 13 ms; flip angle = 120°; 33 slices; slice thickness 4 mm; matrix 128 × 128; FOV 220 mm].
41-1	5963-5966	Two	_
41-2	5967-5971	sets	_
41-3	5972-5974	of	_
41-4	5975-5985	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
41-5	5986-5992	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
41-6	5993-5997	were	_
41-7	5998-6006	acquired	_
41-8	6007-6010	for	_
41-9	6011-6023	registration	_
41-10	6024-6026	of	_
41-11	6027-6037	functional	_
41-12	6038-6042	data	_
41-13	6043-6044	:	_
41-14	6045-6046	a	_
41-15	6047-6049	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-16	6050-6058	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-17	6059-6072	magnetization	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-18	6073-6081	prepared	_
41-19	6082-6099	rapid-acquisition	http://maven.renci.org/NeuroBridge/neurobridge#Education
41-20	6100-6108	gradient	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
41-21	6109-6113	echo	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
41-22	6114-6119	image	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
41-23	6120-6121	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
41-24	6122-6128	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
41-25	6129-6130	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
41-26	6131-6132	[	_
41-27	6133-6135	TR	_
41-28	6136-6137	,	_
41-29	6138-6142	1900	_
41-30	6143-6145	ms	_
41-31	6146-6147	;	_
41-32	6148-6150	TE	_
41-33	6151-6155	3.43	_
41-34	6156-6158	ms	_
41-35	6159-6160	;	_
41-36	6161-6165	flip	_
41-37	6166-6171	angle	_
41-38	6172-6173	=	_
41-39	6174-6176	9°	_
41-40	6177-6178	;	_
41-41	6179-6182	160	_
41-42	6183-6191	sagittal	_
41-43	6192-6198	slices	_
41-44	6199-6200	;	_
41-45	6201-6206	slice	_
41-46	6207-6216	thickness	_
41-47	6217-6218	1	_
41-48	6219-6221	mm	_
41-49	6222-6223	;	_
41-50	6224-6230	matrix	_
41-51	6231-6234	256	_
41-52	6235-6236	×	_
41-53	6237-6240	256	_
41-54	6241-6242	;	_
41-55	6243-6246	FOV	_
41-56	6247-6250	256	_
41-57	6251-6253	mm	_
41-58	6254-6255	]	_
41-59	6256-6257	;	_
41-60	6258-6261	and	_
41-61	6262-6263	a	_
41-62	6264-6275	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
41-63	6276-6293	matched-bandwidth	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
41-64	6294-6309	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
41-65	6310-6314	scan	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
41-66	6315-6319	with	_
41-67	6320-6323	the	_
41-68	6324-6328	same	_
41-69	6329-6334	slice	_
41-70	6335-6347	prescription	_
41-71	6348-6350	as	_
41-72	6351-6354	the	_
41-73	6355-6358	EPI	_
41-74	6359-6360	[	_
41-75	6361-6363	TR	_
41-76	6364-6365	,	_
41-77	6366-6370	6540	_
41-78	6371-6373	ms	_
41-79	6374-6375	;	_
41-80	6376-6378	TE	_
41-81	6379-6380	,	_
41-82	6381-6383	13	_
41-83	6384-6386	ms	_
41-84	6387-6388	;	_
41-85	6389-6393	flip	_
41-86	6394-6399	angle	_
41-87	6400-6401	=	_
41-88	6402-6406	120°	_
41-89	6407-6408	;	_
41-90	6409-6411	33	_
41-91	6412-6418	slices	_
41-92	6419-6420	;	_
41-93	6421-6426	slice	_
41-94	6427-6436	thickness	_
41-95	6437-6438	4	_
41-96	6439-6441	mm	_
41-97	6442-6443	;	_
41-98	6444-6450	matrix	_
41-99	6451-6454	128	_
41-100	6455-6456	×	_
41-101	6457-6460	128	_
41-102	6461-6462	;	_
41-103	6463-6466	FOV	_
41-104	6467-6470	220	_
41-105	6471-6473	mm	_
41-106	6474-6475	]	_
41-107	6476-6477	.	_

Text=Preprocessing and data analysis was performed with the FMRIB Software Library (FSL v5.0; Analysis Group, Oxford, UK).
42-1	6478-6491	Preprocessing	_
42-2	6492-6495	and	_
42-3	6496-6500	data	_
42-4	6501-6509	analysis	_
42-5	6510-6513	was	_
42-6	6514-6523	performed	_
42-7	6524-6528	with	_
42-8	6529-6532	the	_
42-9	6533-6538	FMRIB	_
42-10	6539-6547	Software	_
42-11	6548-6555	Library	_
42-12	6556-6557	(	_
42-13	6558-6561	FSL	_
42-14	6562-6566	v5.0	_
42-15	6567-6568	;	_
42-16	6569-6577	Analysis	_
42-17	6578-6583	Group	_
42-18	6584-6585	,	_
42-19	6586-6592	Oxford	_
42-20	6593-6594	,	_
42-21	6595-6597	UK	_
42-22	6598-6599	)	_
42-23	6600-6601	.	_

Text=To compensate for any head motion, images were realigned to the middle volume using MCFLIRT.
43-1	6602-6604	To	_
43-2	6605-6615	compensate	_
43-3	6616-6619	for	_
43-4	6620-6623	any	_
43-5	6624-6628	head	_
43-6	6629-6635	motion	_
43-7	6636-6637	,	_
43-8	6638-6644	images	_
43-9	6645-6649	were	_
43-10	6650-6659	realigned	_
43-11	6660-6662	to	_
43-12	6663-6666	the	_
43-13	6667-6673	middle	_
43-14	6674-6680	volume	_
43-15	6681-6686	using	_
43-16	6687-6694	MCFLIRT	_
43-17	6695-6696	.	_

Text=Movement parameters calculated by MCFLIRT were also modeled in the analysis as nuisance covariates.
44-1	6697-6705	Movement	_
44-2	6706-6716	parameters	_
44-3	6717-6727	calculated	_
44-4	6728-6730	by	_
44-5	6731-6738	MCFLIRT	_
44-6	6739-6743	were	_
44-7	6744-6748	also	_
44-8	6749-6756	modeled	_
44-9	6757-6759	in	_
44-10	6760-6763	the	_
44-11	6764-6772	analysis	_
44-12	6773-6775	as	_
44-13	6776-6784	nuisance	_
44-14	6785-6795	covariates	_
44-15	6796-6797	.	_

Text=Relative mean displacement estimates for the final sample did not exceed 0.5 mm; however, estimates for patients were significantly greater than for controls (patients: M = .18, SD = .11; controls: M = .11, SD = .01; t (49) = 2.94, p <.05).
45-1	6798-6806	Relative	_
45-2	6807-6811	mean	_
45-3	6812-6824	displacement	_
45-4	6825-6834	estimates	_
45-5	6835-6838	for	_
45-6	6839-6842	the	_
45-7	6843-6848	final	_
45-8	6849-6855	sample	_
45-9	6856-6859	did	_
45-10	6860-6863	not	_
45-11	6864-6870	exceed	_
45-12	6871-6874	0.5	_
45-13	6875-6877	mm	_
45-14	6878-6879	;	_
45-15	6880-6887	however	_
45-16	6888-6889	,	_
45-17	6890-6899	estimates	_
45-18	6900-6903	for	_
45-19	6904-6912	patients	_
45-20	6913-6917	were	_
45-21	6918-6931	significantly	_
45-22	6932-6939	greater	_
45-23	6940-6944	than	_
45-24	6945-6948	for	_
45-25	6949-6957	controls	_
45-26	6958-6959	(	_
45-27	6960-6968	patients	_
45-28	6969-6970	:	_
45-29	6971-6972	M	_
45-30	6973-6974	=	_
45-31	6975-6978	.18	_
45-32	6979-6980	,	_
45-33	6981-6983	SD	_
45-34	6984-6985	=	_
45-35	6986-6989	.11	_
45-36	6990-6991	;	_
45-37	6992-7000	controls	_
45-38	7001-7002	:	_
45-39	7003-7004	M	_
45-40	7005-7006	=	_
45-41	7007-7010	.11	_
45-42	7011-7012	,	_
45-43	7013-7015	SD	_
45-44	7016-7017	=	_
45-45	7018-7021	.01	_
45-46	7022-7023	;	_
45-47	7024-7025	t	_
45-48	7026-7027	(	_
45-49	7028-7030	49	_
45-50	7031-7032	)	_
45-51	7033-7034	=	_
45-52	7035-7039	2.94	_
45-53	7040-7041	,	_
45-54	7042-7043	p	_
45-55	7044-7045	<	_
45-56	7046-7049	.05	_
45-57	7050-7051	)	_
45-58	7052-7053	.	_

Text=Two patients had one block (out of three) excluded for excessive head motion (relative mean displacement> 0.5 mm).
46-1	7054-7057	Two	_
46-2	7058-7066	patients	_
46-3	7067-7070	had	_
46-4	7071-7074	one	_
46-5	7075-7080	block	_
46-6	7081-7082	(	_
46-7	7083-7086	out	_
46-8	7087-7089	of	_
46-9	7090-7095	three	_
46-10	7096-7097	)	_
46-11	7098-7106	excluded	_
46-12	7107-7110	for	_
46-13	7111-7120	excessive	_
46-14	7121-7125	head	_
46-15	7126-7132	motion	_
46-16	7133-7134	(	_
46-17	7135-7143	relative	_
46-18	7144-7148	mean	_
46-19	7149-7161	displacement	_
46-20	7162-7163	>	_
46-21	7164-7167	0.5	_
46-22	7168-7170	mm	_
46-23	7171-7172	)	_
46-24	7173-7174	.	_

Text=One patient was excluded from the analysis due to having two out of three blocks with excessive head motion.
47-1	7175-7178	One	_
47-2	7179-7186	patient	_
47-3	7187-7190	was	_
47-4	7191-7199	excluded	_
47-5	7200-7204	from	_
47-6	7205-7208	the	_
47-7	7209-7217	analysis	_
47-8	7218-7221	due	_
47-9	7222-7224	to	_
47-10	7225-7231	having	_
47-11	7232-7235	two	_
47-12	7236-7239	out	_
47-13	7240-7242	of	_
47-14	7243-7248	three	_
47-15	7249-7255	blocks	_
47-16	7256-7260	with	_
47-17	7261-7270	excessive	_
47-18	7271-7275	head	_
47-19	7276-7282	motion	_
47-20	7283-7284	.	_

Text=Following these exclusions, 24 patients with schizophrenia and 27 normal controls were included in the PPI analyses.
48-1	7285-7294	Following	_
48-2	7295-7300	these	_
48-3	7301-7311	exclusions	_
48-4	7312-7313	,	_
48-5	7314-7316	24	_
48-6	7317-7325	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
48-7	7326-7330	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
48-8	7331-7344	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
48-9	7345-7348	and	_
48-10	7349-7351	27	_
48-11	7352-7358	normal	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
48-12	7359-7367	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
48-13	7368-7372	were	_
48-14	7373-7381	included	_
48-15	7382-7384	in	_
48-16	7385-7388	the	_
48-17	7389-7392	PPI	_
48-18	7393-7401	analyses	_
48-19	7402-7403	.	_

Text=The data were temporally filtered with a high-pass filter cutoff of 60 s and spatially smoothed with a 5 mm full width half maximum Gaussian kernel in three dimensions.
49-1	7404-7407	The	_
49-2	7408-7412	data	_
49-3	7413-7417	were	_
49-4	7418-7428	temporally	_
49-5	7429-7437	filtered	_
49-6	7438-7442	with	_
49-7	7443-7444	a	_
49-8	7445-7454	high-pass	_
49-9	7455-7461	filter	_
49-10	7462-7468	cutoff	_
49-11	7469-7471	of	_
49-12	7472-7474	60	_
49-13	7475-7476	s	_
49-14	7477-7480	and	_
49-15	7481-7490	spatially	_
49-16	7491-7499	smoothed	_
49-17	7500-7504	with	_
49-18	7505-7506	a	_
49-19	7507-7508	5	_
49-20	7509-7511	mm	_
49-21	7512-7516	full	_
49-22	7517-7522	width	_
49-23	7523-7527	half	_
49-24	7528-7535	maximum	_
49-25	7536-7544	Gaussian	_
49-26	7545-7551	kernel	_
49-27	7552-7554	in	_
49-28	7555-7560	three	_
49-29	7561-7571	dimensions	_
49-30	7572-7573	.	_

Text=Registration was carried out using FSL ’ s FLIRT.
50-1	7574-7586	Registration	_
50-2	7587-7590	was	_
50-3	7591-7598	carried	_
50-4	7599-7602	out	_
50-5	7603-7608	using	_
50-6	7609-7612	FSL	_
50-7	7613-7614	’	_
50-8	7615-7616	s	_
50-9	7617-7622	FLIRT	_
50-10	7623-7624	.	_

Text=Each block of individual EPI data was registered first to the co-planar matched-bandwidth T2-weighted image, then to the T1-weighted MPRAGE (both using affine transformations; 6 degrees of freedom) and finally, to Montreal Neurological Institute (MNI) standard space (affine transformation, 12 degrees of freedom).
51-1	7625-7629	Each	_
51-2	7630-7635	block	_
51-3	7636-7638	of	_
51-4	7639-7649	individual	_
51-5	7650-7653	EPI	_
51-6	7654-7658	data	_
51-7	7659-7662	was	_
51-8	7663-7673	registered	_
51-9	7674-7679	first	_
51-10	7680-7682	to	_
51-11	7683-7686	the	_
51-12	7687-7696	co-planar	_
51-13	7697-7714	matched-bandwidth	_
51-14	7715-7726	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
51-15	7727-7732	image	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
51-16	7733-7734	,	_
51-17	7735-7739	then	_
51-18	7740-7742	to	_
51-19	7743-7746	the	_
51-20	7747-7758	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
51-21	7759-7765	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
51-22	7766-7767	(	_
51-23	7768-7772	both	_
51-24	7773-7778	using	_
51-25	7779-7785	affine	_
51-26	7786-7801	transformations	_
51-27	7802-7803	;	_
51-28	7804-7805	6	_
51-29	7806-7813	degrees	_
51-30	7814-7816	of	_
51-31	7817-7824	freedom	_
51-32	7825-7826	)	_
51-33	7827-7830	and	_
51-34	7831-7838	finally	_
51-35	7839-7840	,	_
51-36	7841-7843	to	_
51-37	7844-7852	Montreal	_
51-38	7853-7865	Neurological	_
51-39	7866-7875	Institute	_
51-40	7876-7877	(	_
51-41	7878-7881	MNI	_
51-42	7882-7883	)	_
51-43	7884-7892	standard	_
51-44	7893-7898	space	_
51-45	7899-7900	(	_
51-46	7901-7907	affine	_
51-47	7908-7922	transformation	_
51-48	7923-7924	,	_
51-49	7925-7927	12	_
51-50	7928-7935	degrees	_
51-51	7936-7938	of	_
51-52	7939-7946	freedom	_
51-53	7947-7948	)	_
51-54	7949-7950	.	_

Text=2.2.3.
52-1	7951-7956	2.2.3	_
52-2	7957-7958	.	_

Text=Behavioral data analysis Task accuracy was recorded as percentage of correct responses during target trials as well as reaction time of correctly performed trials.
53-1	7959-7969	Behavioral	_
53-2	7970-7974	data	_
53-3	7975-7983	analysis	_
53-4	7984-7988	Task	_
53-5	7989-7997	accuracy	_
53-6	7998-8001	was	_
53-7	8002-8010	recorded	_
53-8	8011-8013	as	_
53-9	8014-8024	percentage	_
53-10	8025-8027	of	_
53-11	8028-8035	correct	_
53-12	8036-8045	responses	_
53-13	8046-8052	during	_
53-14	8053-8059	target	_
53-15	8060-8066	trials	_
53-16	8067-8069	as	_
53-17	8070-8074	well	_
53-18	8075-8077	as	_
53-19	8078-8086	reaction	_
53-20	8087-8091	time	_
53-21	8092-8094	of	_
53-22	8095-8104	correctly	_
53-23	8105-8114	performed	_
53-24	8115-8121	trials	_
53-25	8122-8123	.	_

Text=Group differences in accuracy and reaction time were assessed separately using analysis of variance (ANOVA; p <.05).
54-1	8124-8129	Group	_
54-2	8130-8141	differences	_
54-3	8142-8144	in	_
54-4	8145-8153	accuracy	_
54-5	8154-8157	and	_
54-6	8158-8166	reaction	_
54-7	8167-8171	time	_
54-8	8172-8176	were	_
54-9	8177-8185	assessed	_
54-10	8186-8196	separately	_
54-11	8197-8202	using	_
54-12	8203-8211	analysis	_
54-13	8212-8214	of	_
54-14	8215-8223	variance	_
54-15	8224-8225	(	_
54-16	8226-8231	ANOVA	_
54-17	8232-8233	;	_
54-18	8234-8235	p	_
54-19	8236-8237	<	_
54-20	8238-8241	.05	_
54-21	8242-8243	)	_
54-22	8244-8245	.	_

Text=2.2.4.
55-1	8246-8251	2.2.4	_
55-2	8252-8253	.	_

Text=Psychophysiological interaction (PPI) fMRI analysis Functional connectivity within and between dorsal and ventral attention networks during target detection was examined using whole-brain PPI analyses.
56-1	8254-8273	Psychophysiological	_
56-2	8274-8285	interaction	_
56-3	8286-8287	(	_
56-4	8288-8291	PPI	_
56-5	8292-8293	)	_
56-6	8294-8298	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
56-7	8299-8307	analysis	_
56-8	8308-8318	Functional	_
56-9	8319-8331	connectivity	_
56-10	8332-8338	within	_
56-11	8339-8342	and	_
56-12	8343-8350	between	_
56-13	8351-8357	dorsal	_
56-14	8358-8361	and	_
56-15	8362-8369	ventral	_
56-16	8370-8379	attention	_
56-17	8380-8388	networks	_
56-18	8389-8395	during	_
56-19	8396-8402	target	_
56-20	8403-8412	detection	_
56-21	8413-8416	was	_
56-22	8417-8425	examined	_
56-23	8426-8431	using	_
56-24	8432-8443	whole-brain	_
56-25	8444-8447	PPI	_
56-26	8448-8456	analyses	_
56-27	8457-8458	.	_

Text=Seed regions of interest (ROI) were created by placing a 9 mm radius sphere around the coordinates listed below.
57-1	8459-8463	Seed	_
57-2	8464-8471	regions	_
57-3	8472-8474	of	_
57-4	8475-8483	interest	_
57-5	8484-8485	(	_
57-6	8486-8489	ROI	_
57-7	8490-8491	)	_
57-8	8492-8496	were	_
57-9	8497-8504	created	_
57-10	8505-8507	by	_
57-11	8508-8515	placing	_
57-12	8516-8517	a	_
57-13	8518-8519	9	_
57-14	8520-8522	mm	_
57-15	8523-8529	radius	_
57-16	8530-8536	sphere	_
57-17	8537-8543	around	_
57-18	8544-8547	the	_
57-19	8548-8559	coordinates	_
57-20	8560-8566	listed	_
57-21	8567-8572	below	_
57-22	8573-8574	.	_

Text=Locations of ROI are illustrated in Figure 1.
58-1	8575-8584	Locations	_
58-2	8585-8587	of	_
58-3	8588-8591	ROI	_
58-4	8592-8595	are	_
58-5	8596-8607	illustrated	_
58-6	8608-8610	in	_
58-7	8611-8617	Figure	_
58-8	8618-8619	1	_
58-9	8620-8621	.	_

Text=The seed regions for the ventral attention network (right TPJ) and the dorsal network (right IPS) were defined based on peak coordinates identified by a recent meta-analysis of visual and auditory oddball tasks in healthy controls (right TPJ MNI coordinates: 56, -38,22; right IPS MNI coordinates: 42, -48,44).
59-1	8622-8625	The	_
59-2	8626-8630	seed	_
59-3	8631-8638	regions	_
59-4	8639-8642	for	_
59-5	8643-8646	the	_
59-6	8647-8654	ventral	_
59-7	8655-8664	attention	_
59-8	8665-8672	network	_
59-9	8673-8674	(	_
59-10	8675-8680	right	_
59-11	8681-8684	TPJ	_
59-12	8685-8686	)	_
59-13	8687-8690	and	_
59-14	8691-8694	the	_
59-15	8695-8701	dorsal	_
59-16	8702-8709	network	_
59-17	8710-8711	(	_
59-18	8712-8717	right	_
59-19	8718-8721	IPS	_
59-20	8722-8723	)	_
59-21	8724-8728	were	_
59-22	8729-8736	defined	_
59-23	8737-8742	based	_
59-24	8743-8745	on	_
59-25	8746-8750	peak	_
59-26	8751-8762	coordinates	_
59-27	8763-8773	identified	_
59-28	8774-8776	by	_
59-29	8777-8778	a	_
59-30	8779-8785	recent	_
59-31	8786-8799	meta-analysis	_
59-32	8800-8802	of	_
59-33	8803-8809	visual	_
59-34	8810-8813	and	_
59-35	8814-8822	auditory	_
59-36	8823-8830	oddball	_
59-37	8831-8836	tasks	_
59-38	8837-8839	in	_
59-39	8840-8847	healthy	_
59-40	8848-8856	controls	_
59-41	8857-8858	(	_
59-42	8859-8864	right	_
59-43	8865-8868	TPJ	_
59-44	8869-8872	MNI	_
59-45	8873-8884	coordinates	_
59-46	8885-8886	:	_
59-47	8887-8889	56	_
59-48	8890-8891	,	_
59-49	8892-8898	-38,22	_
59-50	8899-8900	;	_
59-51	8901-8906	right	_
59-52	8907-8910	IPS	_
59-53	8911-8914	MNI	_
59-54	8915-8926	coordinates	_
59-55	8927-8928	:	_
59-56	8929-8931	42	_
59-57	8932-8933	,	_
59-58	8934-8940	-48,44	_
59-59	8941-8942	)	_
59-60	8943-8944	.	_

Text=The seed ROI were defined at the group level in standard space and projected back to each individual subject ’ s preprocessed functional data in their native space.
60-1	8945-8948	The	_
60-2	8949-8953	seed	_
60-3	8954-8957	ROI	_
60-4	8958-8962	were	_
60-5	8963-8970	defined	_
60-6	8971-8973	at	_
60-7	8974-8977	the	_
60-8	8978-8983	group	_
60-9	8984-8989	level	_
60-10	8990-8992	in	_
60-11	8993-9001	standard	_
60-12	9002-9007	space	_
60-13	9008-9011	and	_
60-14	9012-9021	projected	_
60-15	9022-9026	back	_
60-16	9027-9029	to	_
60-17	9030-9034	each	_
60-18	9035-9045	individual	_
60-19	9046-9053	subject	_
60-20	9054-9055	’	_
60-21	9056-9057	s	_
60-22	9058-9070	preprocessed	_
60-23	9071-9081	functional	_
60-24	9082-9086	data	_
60-25	9087-9089	in	_
60-26	9090-9095	their	_
60-27	9096-9102	native	_
60-28	9103-9108	space	_
60-29	9109-9110	.	_

Text=The time course from each seed ROI was then extracted for each subject.
61-1	9111-9114	The	_
61-2	9115-9119	time	_
61-3	9120-9126	course	_
61-4	9127-9131	from	_
61-5	9132-9136	each	_
61-6	9137-9141	seed	_
61-7	9142-9145	ROI	_
61-8	9146-9149	was	_
61-9	9150-9154	then	_
61-10	9155-9164	extracted	_
61-11	9165-9168	for	_
61-12	9169-9173	each	_
61-13	9174-9181	subject	_
61-14	9182-9183	.	_

Text=A lower-level general linear model (GLM) was constructed for each subject using FSL ’ s fMRI Expert Analysis Tool (FEAT) with four main regressors.
62-1	9184-9185	A	_
62-2	9186-9197	lower-level	_
62-3	9198-9205	general	_
62-4	9206-9212	linear	_
62-5	9213-9218	model	_
62-6	9219-9220	(	_
62-7	9221-9224	GLM	_
62-8	9225-9226	)	_
62-9	9227-9230	was	_
62-10	9231-9242	constructed	_
62-11	9243-9246	for	_
62-12	9247-9251	each	_
62-13	9252-9259	subject	_
62-14	9260-9265	using	_
62-15	9266-9269	FSL	_
62-16	9270-9271	’	_
62-17	9272-9273	s	_
62-18	9274-9278	fMRI	_
62-19	9279-9285	Expert	_
62-20	9286-9294	Analysis	_
62-21	9295-9299	Tool	_
62-22	9300-9301	(	_
62-23	9302-9306	FEAT	_
62-24	9307-9308	)	_
62-25	9309-9313	with	_
62-26	9314-9318	four	_
62-27	9319-9323	main	_
62-28	9324-9334	regressors	_
62-29	9335-9336	.	_

Text=A psychological regressor represented the experimental task variable of interest (“ targets ” vs “ non-targets ”), modeled by convolution with a double-gamma canonical hemodynamic response function.
63-1	9337-9338	A	_
63-2	9339-9352	psychological	_
63-3	9353-9362	regressor	_
63-4	9363-9374	represented	_
63-5	9375-9378	the	_
63-6	9379-9391	experimental	_
63-7	9392-9396	task	_
63-8	9397-9405	variable	_
63-9	9406-9408	of	_
63-10	9409-9417	interest	_
63-11	9418-9419	(	_
63-12	9420-9421	“	_
63-13	9422-9429	targets	_
63-14	9430-9431	”	_
63-15	9432-9434	vs	_
63-16	9435-9436	“	_
63-17	9437-9448	non-targets	_
63-18	9449-9450	”	_
63-19	9451-9452	)	_
63-20	9453-9454	,	_
63-21	9455-9462	modeled	_
63-22	9463-9465	by	_
63-23	9466-9477	convolution	_
63-24	9478-9482	with	_
63-25	9483-9484	a	_
63-26	9485-9497	double-gamma	_
63-27	9498-9507	canonical	_
63-28	9508-9519	hemodynamic	_
63-29	9520-9528	response	_
63-30	9529-9537	function	_
63-31	9538-9539	.	_

Text=A physiological regressor represented task-related BOLD activation in a priori seed regions (right TPJ for the ventral network and right IPS for the dorsal network).
64-1	9540-9541	A	_
64-2	9542-9555	physiological	_
64-3	9556-9565	regressor	_
64-4	9566-9577	represented	_
64-5	9578-9590	task-related	_
64-6	9591-9595	BOLD	_
64-7	9596-9606	activation	_
64-8	9607-9609	in	_
64-9	9610-9611	a	_
64-10	9612-9618	priori	_
64-11	9619-9623	seed	_
64-12	9624-9631	regions	_
64-13	9632-9633	(	_
64-14	9634-9639	right	_
64-15	9640-9643	TPJ	_
64-16	9644-9647	for	_
64-17	9648-9651	the	_
64-18	9652-9659	ventral	_
64-19	9660-9667	network	_
64-20	9668-9671	and	_
64-21	9672-9677	right	_
64-22	9678-9681	IPS	_
64-23	9682-9685	for	_
64-24	9686-9689	the	_
64-25	9690-9696	dorsal	_
64-26	9697-9704	network	_
64-27	9705-9706	)	_
64-28	9707-9708	.	_

Text=An interaction regressor was used to model the interaction between the “ targets ” vs “ non-targets ” psychological regressor and the physiological regressor.
65-1	9709-9711	An	_
65-2	9712-9723	interaction	_
65-3	9724-9733	regressor	_
65-4	9734-9737	was	_
65-5	9738-9742	used	_
65-6	9743-9745	to	_
65-7	9746-9751	model	_
65-8	9752-9755	the	_
65-9	9756-9767	interaction	_
65-10	9768-9775	between	_
65-11	9776-9779	the	_
65-12	9780-9781	“	_
65-13	9782-9789	targets	_
65-14	9790-9791	”	_
65-15	9792-9794	vs	_
65-16	9795-9796	“	_
65-17	9797-9808	non-targets	_
65-18	9809-9810	”	_
65-19	9811-9824	psychological	_
65-20	9825-9834	regressor	_
65-21	9835-9838	and	_
65-22	9839-9842	the	_
65-23	9843-9856	physiological	_
65-24	9857-9866	regressor	_
65-25	9867-9868	.	_

Text=An additional regressor of non-interest modeled shared variance between targets and non-targets (i.e., “ targets ” + “ non-targets ”) to improve overall model fit.
66-1	9869-9871	An	_
66-2	9872-9882	additional	_
66-3	9883-9892	regressor	_
66-4	9893-9895	of	_
66-5	9896-9908	non-interest	_
66-6	9909-9916	modeled	_
66-7	9917-9923	shared	_
66-8	9924-9932	variance	_
66-9	9933-9940	between	_
66-10	9941-9948	targets	_
66-11	9949-9952	and	_
66-12	9953-9964	non-targets	_
66-13	9965-9966	(	_
66-14	9967-9971	i.e.	_
66-15	9972-9973	,	_
66-16	9974-9975	“	_
66-17	9976-9983	targets	_
66-18	9984-9985	”	_
66-19	9986-9987	+	_
66-20	9988-9989	“	_
66-21	9990-10001	non-targets	_
66-22	10002-10003	”	_
66-23	10004-10005	)	_
66-24	10006-10008	to	_
66-25	10009-10016	improve	_
66-26	10017-10024	overall	_
66-27	10025-10030	model	_
66-28	10031-10034	fit	_
66-29	10035-10036	.	_

Text=Six parameters for motion correction were included as regressors of non-interest.
67-1	10037-10040	Six	_
67-2	10041-10051	parameters	_
67-3	10052-10055	for	_
67-4	10056-10062	motion	_
67-5	10063-10073	correction	_
67-6	10074-10078	were	_
67-7	10079-10087	included	_
67-8	10088-10090	as	_
67-9	10091-10101	regressors	_
67-10	10102-10104	of	_
67-11	10105-10117	non-interest	_
67-12	10118-10119	.	_

Text=From the lower-level parameter estimate maps, a second-level fixed-effects analysis was performed to average across the three task blocks for each participant.
68-1	10120-10124	From	_
68-2	10125-10128	the	_
68-3	10129-10140	lower-level	_
68-4	10141-10150	parameter	_
68-5	10151-10159	estimate	_
68-6	10160-10164	maps	_
68-7	10165-10166	,	_
68-8	10167-10168	a	_
68-9	10169-10181	second-level	_
68-10	10182-10195	fixed-effects	_
68-11	10196-10204	analysis	_
68-12	10205-10208	was	_
68-13	10209-10218	performed	_
68-14	10219-10221	to	_
68-15	10222-10229	average	_
68-16	10230-10236	across	_
68-17	10237-10240	the	_
68-18	10241-10246	three	_
68-19	10247-10251	task	_
68-20	10252-10258	blocks	_
68-21	10259-10262	for	_
68-22	10263-10267	each	_
68-23	10268-10279	participant	_
68-24	10280-10281	.	_

Text=The resulting contrast images were entered into a group-level random-effects analysis using the FLAME (FMRIB ’ s Local Analysis of Mixed Effects) stage 1 module.
69-1	10282-10285	The	_
69-2	10286-10295	resulting	_
69-3	10296-10304	contrast	_
69-4	10305-10311	images	_
69-5	10312-10316	were	_
69-6	10317-10324	entered	_
69-7	10325-10329	into	_
69-8	10330-10331	a	_
69-9	10332-10343	group-level	_
69-10	10344-10358	random-effects	_
69-11	10359-10367	analysis	_
69-12	10368-10373	using	_
69-13	10374-10377	the	_
69-14	10378-10383	FLAME	_
69-15	10384-10385	(	_
69-16	10386-10391	FMRIB	_
69-17	10392-10393	’	_
69-18	10394-10395	s	_
69-19	10396-10401	Local	_
69-20	10402-10410	Analysis	_
69-21	10411-10413	of	_
69-22	10414-10419	Mixed	_
69-23	10420-10427	Effects	_
69-24	10428-10429	)	_
69-25	10430-10435	stage	_
69-26	10436-10437	1	_
69-27	10438-10444	module	_
69-28	10445-10446	.	_

Text=At the group level, participant task performance was included to ensure that group effects were not attributable to group differences in accuracy and reaction time.
70-1	10447-10449	At	_
70-2	10450-10453	the	_
70-3	10454-10459	group	_
70-4	10460-10465	level	_
70-5	10466-10467	,	_
70-6	10468-10479	participant	_
70-7	10480-10484	task	_
70-8	10485-10496	performance	_
70-9	10497-10500	was	_
70-10	10501-10509	included	_
70-11	10510-10512	to	_
70-12	10513-10519	ensure	_
70-13	10520-10524	that	_
70-14	10525-10530	group	_
70-15	10531-10538	effects	_
70-16	10539-10543	were	_
70-17	10544-10547	not	_
70-18	10548-10560	attributable	_
70-19	10561-10563	to	_
70-20	10564-10569	group	_
70-21	10570-10581	differences	_
70-22	10582-10584	in	_
70-23	10585-10593	accuracy	_
70-24	10594-10597	and	_
70-25	10598-10606	reaction	_
70-26	10607-10611	time	_
70-27	10612-10613	.	_

Text=Results were subjected to pre-threshold masking to constrain the search to areas activated by the target vs non-target contrast from the regional analysis of data (using a threshold of Z> 3.1, p <.05).
71-1	10614-10621	Results	_
71-2	10622-10626	were	_
71-3	10627-10636	subjected	_
71-4	10637-10639	to	_
71-5	10640-10653	pre-threshold	_
71-6	10654-10661	masking	_
71-7	10662-10664	to	_
71-8	10665-10674	constrain	_
71-9	10675-10678	the	_
71-10	10679-10685	search	_
71-11	10686-10688	to	_
71-12	10689-10694	areas	_
71-13	10695-10704	activated	_
71-14	10705-10707	by	_
71-15	10708-10711	the	_
71-16	10712-10718	target	_
71-17	10719-10721	vs	_
71-18	10722-10732	non-target	_
71-19	10733-10741	contrast	_
71-20	10742-10746	from	_
71-21	10747-10750	the	_
71-22	10751-10759	regional	_
71-23	10760-10768	analysis	_
71-24	10769-10771	of	_
71-25	10772-10776	data	_
71-26	10777-10778	(	_
71-27	10779-10784	using	_
71-28	10785-10786	a	_
71-29	10787-10796	threshold	_
71-30	10797-10799	of	_
71-31	10800-10801	Z	_
71-32	10802-10803	>	_
71-33	10804-10807	3.1	_
71-34	10808-10809	,	_
71-35	10810-10811	p	_
71-36	10812-10813	<	_
71-37	10814-10817	.05	_
71-38	10818-10819	)	_
71-39	10820-10821	.	_

Text=This masking served to mitigate effects of a large amount of de-activation present in all subjects during non-target stimuli.
72-1	10822-10826	This	_
72-2	10827-10834	masking	_
72-3	10835-10841	served	_
72-4	10842-10844	to	_
72-5	10845-10853	mitigate	_
72-6	10854-10861	effects	_
72-7	10862-10864	of	_
72-8	10865-10866	a	_
72-9	10867-10872	large	_
72-10	10873-10879	amount	_
72-11	10880-10882	of	_
72-12	10883-10896	de-activation	_
72-13	10897-10904	present	_
72-14	10905-10907	in	_
72-15	10908-10911	all	_
72-16	10912-10920	subjects	_
72-17	10921-10927	during	_
72-18	10928-10938	non-target	_
72-19	10939-10946	stimuli	_
72-20	10947-10948	.	_

Text=Finally, resulting within group activation maps were thresholded at Z> 2.3, p <0.05, cluster-corrected for whole-brain multiple comparisons to control for family wise Type I error rate.
73-1	10949-10956	Finally	_
73-2	10957-10958	,	_
73-3	10959-10968	resulting	_
73-4	10969-10975	within	_
73-5	10976-10981	group	_
73-6	10982-10992	activation	_
73-7	10993-10997	maps	_
73-8	10998-11002	were	_
73-9	11003-11014	thresholded	_
73-10	11015-11017	at	_
73-11	11018-11019	Z	_
73-12	11020-11021	>	_
73-13	11022-11025	2.3	_
73-14	11026-11027	,	_
73-15	11028-11029	p	_
73-16	11030-11031	<	_
73-17	11032-11036	0.05	_
73-18	11037-11038	,	_
73-19	11039-11056	cluster-corrected	_
73-20	11057-11060	for	_
73-21	11061-11072	whole-brain	_
73-22	11073-11081	multiple	_
73-23	11082-11093	comparisons	_
73-24	11094-11096	to	_
73-25	11097-11104	control	_
73-26	11105-11108	for	_
73-27	11109-11115	family	_
73-28	11116-11120	wise	_
73-29	11121-11125	Type	_
73-30	11126-11127	I	_
73-31	11128-11133	error	_
73-32	11134-11138	rate	_
73-33	11139-11140	.	_

